Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: a population-based cohort study of systemically treated patients
Menée à partir de données 2008-2017 du registre néerlandais des cancers portant sur 1 458 patientes atteintes d'un cancer du sein HER2+ de stade métastatique de novo, cette étude analyse l'évolution de la survie globale
Aim: This study aims to determine whether real-world overall survival (OS) of patients with de Novo HER2-positive (HER2+) metastatic breast cancer (MBC) in the Netherlands improved over time.
Methods: Data of patients diagnosed with de Novo HER2+ MBC in 2008-2017 were retrieved from the Netherlands Cancer Registry. OS was estimated per two-year period using the Kaplan-Meier method and compared using the log-rank test for trend and the multivariable Cox proportional hazards analysis, adjusted for baseline characteristics and local therapy. First-given systemic and local therapy use was determined per two-year period.
Results: Among 1,458 patients included, 99% (1,452/1,458) were female and 53% (775/1,458) aged 50-74 years at diagnosis. Comparing patients diagnosed with de Novo HER2+ MBC in 2008-2009 versus 2016-2017, the median OS improved from 30·9 months (95%CI:25·0-35·4) to 57·3 months (95%CI:46·7-68·1) (p-value for trend<0·001) (adjusted hazard rate ratio =0·49, 95%CI:0·40-0·59). The use of any HER2-targeted therapy increased from 64% (178/279) to 84% (287/340), while the use of pertuzumab-based therapy increased from 0% to 67% (227/340) over the same period. The use of surgery remained stable over time, while radiotherapy use for both the primary tumour and metastases increased in recent years, from 16% (44/279) and 15% (42/279) in 2008-2009 to 22% (76/340) and 26% (88/340) in 2016-2017, respectively.
Conclusion: OS has doubled over ten years, for patients diagnosed with de Novo HER2+ MBC in the Netherlands between 2008 and 2017. No change in metastatic presentation was observed over time, suggesting the improved OS is most likely explained by treatment improvements.
European Journal of Cancer , résuméHER2+ 2025